A2M and Cirrhosis: Even though α2M levels are increased in patients, α2M is incapable of restoring the thrombin decay capacity or thrombin generation itself in cirrhosis patients, but the percentage of thrombin that was inhibited by this secondary thrombin inhibitor was increased up to 3-fold compared to the values found in healthy subjects.